Lance Armstrong Endurance Hypothesized Full Protocol

What Lance Armstrong Has Said He Took

Armstrong's account is the most direct primary source available. In his January 2013 interview with Oprah Winfrey, he confirmed using EPO (erythropoietin), testosterone, human growth hormone, cortisone, and autologous blood transfusions during his cycling career. He described EPO as the most widespread drug in professional cycling at the time and said, "I looked up the definition of 'cheat' and the definition of 'cheat' is to gain an advantage on a rival or foe. I didn't view it that way."

The U.S. Anti-Doping Agency's October 2012 Reasoned Decision cited testimony from 26 witnesses, including 15 former teammates. That document described a "sophisticated, professionalized and successful doping program" operated by Armstrong and the United States Postal Service Pro Cycling Team. No subsequent legal proceeding overturned those factual findings.

What the USADA Report Confirmed

The USADA Reasoned Decision detailed transfusion schedules, EPO micro-dosing strategies, and testosterone application. Former teammate George Hincapie, in sworn testimony cited by USADA, confirmed that EPO and testosterone were used by multiple team members across multiple Tour de France races.

Armstrong's Own Timeline

Armstrong has since discussed his drug use on multiple podcast appearances, including The Tim Ferriss Show and his own podcast "THEMOVE." His public statements align with the USADA timeline: heavy use through the early 2000s, a claimed retirement in 2005, return to cycling in 2009, and additional testing irregularities flagged by the UCI around that return.

Erythropoietin (EPO): The Centerpiece Compound

EPO is a glycoprotein hormone produced primarily by the kidneys in response to hypoxia. It signals bone marrow to increase red blood cell production, raising hematocrit and oxygen-carrying capacity. Recombinant human EPO (rhEPO, brand name Epogen/Procrit) was approved by the FDA in 1989 for anemia in chronic kidney disease and chemotherapy patients. [1]

Physiological Effects on Endurance Performance

Red blood cell mass directly limits maximal oxygen uptake. A controlled crossover trial published in the Journal of Applied Physiology found that rhEPO administration for four weeks increased VO2max by 5.8% and time-trial performance by 3.9% in well-trained cyclists. [2] A separate randomized trial in Medicine and Science in Sports and Exercise confirmed hematocrit increases from a mean of 42.7% to 49.9% after three weeks of rhEPO at 20 IU/kg three times per week. [3]

The UCI introduced a hematocrit ceiling of 50% in 1997, below the threshold for formal doping violation but designed to reduce EPO abuse. USADA's report suggested Armstrong's team used micro-dosing protocols timed to avoid detection windows.

Pharmacokinetics and Detection

Recombinant EPO has a plasma half-life of approximately 4 to 8 hours after intravenous dosing and 24 hours after subcutaneous injection. [4] The World Anti-Doping Agency (WADA) urine test for rhEPO, based on isoelectric focusing, can detect the drug approximately 3 to 4 days after the last subcutaneous dose. Longitudinal hematological profiling through the Athlete Biological Passport has substantially extended the detection window by flagging abnormal patterns over time. [5]

Cardiovascular Risks

Supraphysiologic EPO use raises blood viscosity. A retrospective analysis of professional cycling deaths between 1987 and 1990 attributed dozens of unexplained cardiac events to suspected EPO use, though definitive causation was not established. [6] Controlled research confirms that rhEPO increases whole-blood viscosity in a dose-dependent manner, with implications for thromboembolic risk. [7]

Testosterone: Recovery and Power

Testosterone was the second compound Armstrong confirmed. In endurance sport, exogenous testosterone is used less for acute strength gains and more for accelerated recovery, red blood cell stimulation, and maintenance of lean mass during caloric restriction.

Anabolic Effects Relevant to Cycling

Testosterone increases erythropoiesis independently of EPO by stimulating erythropoietin secretion in the kidneys and by direct effects on erythroid progenitor cells. [8] A landmark NEJM trial (Bhasin et al., 1996, N=43) demonstrated that 600 mg testosterone enanthate per week for 10 weeks increased fat-free mass by 6.1 kg and muscle strength by 38% in the squat even without exercise, compared with 1.9 kg and 9% in the placebo-exercise group. [9] The doses relevant to endurance doping are generally lower, aimed at maintaining muscle protein synthesis and red cell mass rather than bodybuilder-level hypertrophy.

Delivery and Masking

USADA testimony described transdermal testosterone application on rest days, a strategy designed to keep the testosterone-to-epitestosterone (T/E) ratio within the then-permitted threshold of 6:1. Exogenous testosterone raises the T/E ratio; cyclists timed applications to allow partial clearance before testing. The T/E ratio test has largely been supplemented by carbon isotope ratio (CIR) testing, which distinguishes synthetic from endogenous testosterone regardless of concentration. [10]

Testosterone's FDA-Approved Context

For clinical reference, the FDA-approved indication for testosterone is hypogonadism, defined as morning total testosterone below 300 ng/dL confirmed on two separate measurements, according to the American Urological Association guideline. [11] The doses used for TRT (typically 75 to 100 mg testosterone cypionate weekly) differ substantially from the supraphysiologic doses alleged in the USADA report.

Human Growth Hormone: Lean Mass and Recovery

Armstrong confirmed HGH use in the Oprah interview. Growth hormone (GH) stimulates IGF-1 production in the liver, promotes lipolysis, and supports connective tissue repair. Its direct ergogenic effect in trained athletes is debated.

What the Clinical Evidence Shows

A Cochrane systematic review of GH supplementation in athletes (Liu et al., 2008) found that GH increased lean body mass by 2.1 kg and reduced fat mass but produced no statistically significant improvement in strength or exercise capacity. [12] A follow-up randomized controlled trial published in Annals of Internal Medicine found that GH plus testosterone produced greater increases in sprint capacity than either agent alone, suggesting synergistic effects on anaerobic power rather than aerobic output. [13]

Detection Timeline

Recombinant GH (rhGH) is detectable via the GH isoform test for approximately 24 to 36 hours after the last injection. The IGF-1 biomarker test extends that window to roughly two weeks. [14] WADA introduced the isoform differential immunoassay in 2004 Olympic testing.

Blood Transfusions: The Autologous Advantage

Beyond pharmacological agents, USADA documented autologous blood transfusions: blood drawn weeks before a race, stored, and re-infused during competition to acutely raise hematocrit above the 50% ceiling without triggering a direct drug test.

Hemodynamic Effects

Re-infusion of one unit (approximately 450 mL) of stored autologous blood raises hemoglobin by approximately 1 g/dL and hematocrit by 3 percentage points. [15] A randomized controlled trial in the British Journal of Sports Medicine found that autologous blood re-infusion improved 3 km time-trial performance by 1.4% in trained runners. [16]

How Teams Concealed It

USADA testimony described refrigerated blood bags transported in team vehicles and administered via IV in hotel rooms. Autologous transfusion leaves no pharmacological marker; detection relies on flow cytometry identifying stored (older) red cells mixed with the athlete's fresh red cell population. This test was not routine during Armstrong's primary racing years.

Cortisone: The Legal Cover Story

Cortisone and corticosteroids occupy a unique position in the Armstrong doping narrative. Armstrong obtained a backdated Therapeutic Use Exemption (TUE) for triamcinolone acetonide, a potent corticosteroid, during the 1999 Tour de France. He tested positive for the substance, and the TUE was provided after the fact.

Corticosteroids and Endurance Performance

Corticosteroids suppress inflammation, reduce perceived effort, and promote lipolysis. They are not traditionally categorized as performance-enhancing in the same class as EPO, but a meta-analysis of corticosteroid use in sport found significant improvements in time-to-exhaustion and perceived exertion in cycling protocols. [17] WADA prohibits systemic corticosteroid use during competition without a valid TUE.

The Hypothesized Protocol: Reconstructed Timeline

The following reconstruction integrates Armstrong's public admissions, USADA findings, and pharmacokinetic data. This is labeled inference where it goes beyond confirmed statements.

Pre-Tour phase (12 to 16 weeks out):

• rhEPO subcutaneously, estimated 20 to 50 IU/kg three times per week, based on regimens described in the scientific literature and consistent with USADA testimony patterns. [3]
• Blood drawn for autologous storage (typically 2 to 4 units over 8 to 12 weeks).
• Testosterone (transdermal or injectable ester) on recovery days to maintain muscle protein synthesis.

Race preparation (4 to 6 weeks out):

• EPO dosing tapered or shifted to micro-dosing (smaller, more frequent doses) to stay below hematocrit ceiling while staying inside approximate detection window.
• HGH added to accelerate connective tissue repair after heavy training blocks.

During the Tour (inference based on USADA testimony, not directly confirmed by Armstrong):

• Autologous blood re-infused on rest days or the night before mountain stages.
• Corticosteroid TUE obtained or applied on stages with inflammatory presentations.
• EPO dosing stopped 4 to 5 days before anticipated testing windows.

Post-Tour:

• Testosterone continued for recovery and lean mass preservation.
• All compounds cleared before returning to standard training with team physicians.

Pharmacological Interactions: What the Science Says

Each compound in this hypothesized stack interacts with the others at the physiological level.

EPO and Testosterone Combination on Red Cell Mass

Both EPO and testosterone stimulate erythropoiesis through partially overlapping mechanisms. EPO binds the EPOR receptor on erythroid progenitors; testosterone upregulates EPOR expression and increases endogenous EPO secretion. [8] Using both compounds together produces greater hematocrit elevation than either alone, which is consistent with the documented use pattern.

Growth Hormone and IGF-1 Axis

HGH elevates IGF-1, which has its own anabolic effects on muscle protein synthesis and may reduce muscle protein catabolism during caloric restriction common in stage racing. One controlled study found that GH plus structured endurance training increased VO2max by 1.6% compared with training alone, though the effect was statistically modest. [18]

Corticosteroid Catabolic Risk

Prolonged corticosteroid use produces muscle catabolism, osteoporosis, and adrenal suppression. In the context of a single race, these risks are less acute, but repeated TUE use across multiple Tour seasons compounds long-term exposure risk. The FDA prescribing information for triamcinolone acetonide explicitly lists these adverse effects. [19]

Long-Term Health Consequences: What Research Shows

Armstrong has spoken publicly about his prostate cancer diagnosis in 2024. No direct causal link between his PED use and cancer has been established. The research on exogenous testosterone and prostate cancer risk is mixed.

Testosterone and Prostate Cancer Risk

The Endogenous Hormones and Prostate Cancer Collaborative Group meta-analysis (N=3,886 cases) found no statistically significant association between serum testosterone and prostate cancer risk. [20] A more recent analysis in JAMA Oncology confirmed that testosterone therapy does not appear to increase prostate cancer incidence in hypogonadal men, though monitoring remains standard practice. [21]

Cardiovascular Risk of EPO

A large pharmacovigilance study of patients with chronic kidney disease receiving rhEPO found increased rates of stroke and thromboembolism when target hemoglobin exceeded 13 g/dL. [22] In healthy athletes, the threshold hemoglobin is lower, meaning supraphysiologic EPO use carries cardiovascular risk at hematocrit levels that would be subclinical in a nephrology context.

Polycythemia and Hyperviscosity

Hematocrit above 52 to 53% substantially increases whole-blood viscosity. A study published in Clinical Hemorheology and Microcirculation demonstrated that blood viscosity rises non-linearly above hematocrit of 50%, with a disproportionate increase in low-shear viscosity at values above 55%. [23] This is the mechanism underlying suspected exercise-induced cardiac events in EPO-era cyclists.

What Anti-Doping Science Has Learned From This Case

The Armstrong case directly accelerated the development of the Athlete Biological Passport (ABP), introduced by WADA in 2008 and expanded in 2014.

The Athlete Biological Passport

Rather than testing for a specific drug, the ABP tracks biomarkers over time and flags statistically improbable variations. A longitudinal study of ABP data found that hematological module screening detected 40% more potential violations than direct EPO testing alone. [24] The hematological module monitors hemoglobin, reticulocyte percentage, and the OFF-score (a composite of hematocrit and reticulocyte percentage).

Microdosing and Detection Gaps

A pharmacokinetic modeling study in the British Journal of Pharmacology showed that EPO doses as low as 4 IU/kg could maintain supraphysiologic erythropoiesis without detectable urine drug concentrations if timed 72 hours before testing. [25] The ABP addresses this gap by detecting the erythropoietic effect rather than the drug itself.

Clinical Context: Where These Compounds Are Legitimate

Each substance in this protocol has an FDA-approved clinical use.

EPO in Medicine

Epoetin alfa is approved for anemia associated with chronic kidney disease, HIV treatment with zidovudine, and chemotherapy-induced anemia. [1] Therapeutic dosing is typically 50 to 300 IU/kg three times per week, titrated to a target hemoglobin of 10 to 12 g/dL. Use above 12 g/dL is associated with increased cardiovascular mortality per the FDA black box warning. [1]

Testosterone in Hypogonadism

Testosterone replacement therapy is appropriate for men with confirmed hypogonadism. The Endocrine Society guideline recommends treatment when symptoms of low testosterone coincide with two morning total testosterone measurements below 300 ng/dL. [26] Standard TRT protocols use doses that restore testosterone to mid-normal physiologic range (400 to 700 ng/dL), not the supraphysiologic levels used in sport doping.

Growth Hormone in GH Deficiency

RhGH (somatropin) is approved for adult GH deficiency, typically at doses of 0.2 to 0.4 mg/day subcutaneously, titrated by IGF-1 levels. [27] This is dramatically lower than the doses estimated in athletic doping contexts.